Balance Sheet WuXi Biologics (Cayman) Inc. OTC Markets
Equities
WXXW.Y
US98260N1081
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.180 USD | -0.73% |
|
-5.76% | +2.25% |
| Jun. 05 | Wuxi Biologics Completes Topping Out of Drug Product Facility At Singapore Crdmo Hub | CI |
| May. 31 | Wuxi Biologics adds 69 projects in Jan-April, maintains expected revenue growth | RE |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||
Cash And Equivalents | 9B | 6.4B | 9.67B | 8.28B | 9.21B | |||||
Short Term Investments | 1.15B | 304M | 340M | 1.91B | 5.59B | |||||
Trading Asset Securities, Total | 976M | 2.01B | 1.23B | 524M | 932M | |||||
Total Cash And Short Term Investments | 11.13B | 8.71B | 11.24B | 10.71B | 15.73B | |||||
Accounts Receivable, Total | 3.27B | 5.16B | 6.18B | 5.73B | 7.8B | |||||
Other Receivables | 908M | 617M | 491M | 640M | 1.1B | |||||
Notes Receivable | - | - | - | - | - | |||||
Total Receivables | 4.18B | 5.77B | 6.68B | 6.37B | 8.9B | |||||
Inventory | 1.69B | 2.28B | 1.77B | 1.52B | 1.38B | |||||
Other Current Assets, Total | 2.53B | 1.7B | 1.51B | 4.97B | 2.13B | |||||
Total Current Assets | 19.53B | 18.47B | 21.2B | 23.57B | 28.14B | |||||
Gross Property Plant And Equipment | 21.45B | 28.4B | 33.5B | 32.97B | 35.34B | |||||
Accumulated Depreciation | -1.7B | -2.49B | -3.56B | -4.54B | -5.59B | |||||
Net Property Plant And Equipment | 19.76B | 25.92B | 29.94B | 28.44B | 29.75B | |||||
Long-term Investments | 2.2B | 2.71B | 2.93B | 2.4B | 3.2B | |||||
Goodwill | 1.53B | 1.53B | 1.53B | 1.53B | 1.53B | |||||
Other Intangibles, Total | 601M | 549M | 512M | 442M | 467M | |||||
Accounts Receivable Long-Term | 124M | 109M | 166M | 85.66M | 50.76M | |||||
Deferred Tax Assets Long-Term | 221M | 223M | 236M | 444M | 501M | |||||
Other Long-Term Assets, Total | 68.42M | 58.88M | 60.69M | 66.78M | 55.79M | |||||
Total Assets | 44.03B | 49.56B | 56.58B | 56.98B | 63.7B | |||||
Liabilities | ||||||||||
Accounts Payable, Total | 618M | 794M | 1.42B | 747M | 1.09B | |||||
Accrued Expenses, Total | 832M | 998M | 805M | 828M | 1.16B | |||||
Short-term Borrowings | - | - | - | - | - | |||||
Current Portion of Long-Term Debt | 2.12B | 1.32B | 576M | 2.44B | 874M | |||||
Current Portion of Leases | 104M | 149M | 155M | 184M | 382M | |||||
Current Income Taxes Payable | 558M | 774M | 619M | 648M | 791M | |||||
Unearned Revenue Current, Total | 1.73B | 3.38B | 3.09B | 2.36B | 2.79B | |||||
Other Current Liabilities | 2.29B | 1.9B | 973M | 1.42B | 1.22B | |||||
Total Current Liabilities | 8.26B | 9.32B | 7.64B | 8.62B | 8.31B | |||||
Long-Term Debt | 641M | 1.46B | 1.57B | 201M | 169M | |||||
Long-Term Leases | 1.43B | 1.49B | 2.26B | 2.12B | 1.68B | |||||
Unearned Revenue Non Current | 877M | 949M | 969M | 460M | 341M | |||||
Deferred Tax Liability Non Current | 124M | 132M | 123M | 97.31M | 139M | |||||
Other Non Current Liabilities | - | - | - | - | 21.14M | |||||
Total Liabilities | 11.33B | 13.35B | 12.56B | 11.5B | 10.66B | |||||
Common Stock, Total | 235K | 233K | 235K | 226K | 227K | |||||
Additional Paid In Capital | 27.04B | 22.1B | 24.49B | 23.53B | 22.53B | |||||
Retained Earnings | 7.16B | 11.58B | 14.98B | 18.33B | 23.24B | |||||
Treasury Stock | -2.52B | - | -917M | - | - | |||||
Comprehensive Income and Other | 593M | 1.37B | 1.78B | -46.54M | 1.48B | |||||
Total Common Equity | 32.28B | 35.05B | 40.33B | 41.82B | 47.25B | |||||
Minority Interest | 428M | 1.17B | 3.69B | 3.66B | 5.79B | |||||
Total Equity | 32.71B | 36.21B | 44.02B | 45.48B | 53.04B | |||||
Total Liabilities And Equity | 44.03B | 49.56B | 56.58B | 56.98B | 63.7B | |||||
Supplemental Items | ||||||||||
ECS Total Shares Outstanding on Filing Date | 4.22B | 4.23B | 4.22B | 4.11B | 4.13B | |||||
ECS Total Common Shares Outstanding | 4.22B | 4.23B | 4.22B | 4.11B | 4.13B | |||||
Book Value / Share | 7.64 | 8.29 | 9.55 | 10.19 | 11.43 | |||||
Tangible Book Value | 30.15B | 32.97B | 38.29B | 39.85B | 45.25B | |||||
Tangible Book Value Per Share | 7.14 | 7.8 | 9.07 | 9.7 | 10.95 | |||||
Total Debt | 4.3B | 4.42B | 4.56B | 4.94B | 3.1B | |||||
Net Debt | -6.83B | -4.29B | -6.68B | -5.77B | -12.63B | |||||
Debt Equivalent Oper. Leases | 78.07M | 174M | 297M | 174M | 127M | |||||
Minority Interest, Total (Incl. Fin. Div) | 428M | 1.17B | 3.69B | 3.66B | 5.79B | |||||
Equity Method Investments, Total | - | - | - | - | - | |||||
Account Code - Inventory Valuation | 6 | 6 | 6 | 6 | 6 | |||||
Inventories - Raw Materials, Total | 1.66B | 2.25B | 1.74B | 1.49B | 1.34B | |||||
Inventories - Work In Process, Total | 7.82M | 10.31M | 8.47M | 15.41M | 22.13M | |||||
Inventories - Finished Goods, Total | 16.22M | 20.02M | 16.96M | 15.93M | 14.95M | |||||
Land - (BS) | 2.1B | 2.11B | 6.2B | 7.7B | 7.92B | |||||
Machinery, Total | 5B | 6.03B | 7.63B | 9.39B | 10.11B | |||||
Full Time Employees | 9.86K | 12.37K | 12.74K | 12.58K | 13.25K | |||||
Accumulated Allowance for Doubtful Accounts (Supple) | 303M | 549M | 757M | 969M | 1.14B | |||||
Order Backlog | 86.38B | 142B | 146B | 135B | 166B |
Select your edition
All financial news and data tailored to specific country editions
















